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Abstract 
The enzyme N-myristoyltransferase (NMT) catalyses the essential fatty acylation of 
substrate proteins with myristic acid in eukaryotes and is a validated drug target in the 
parasite Trypanosoma brucei, the causative agent of African trypanosomiasis (sleeping 
sickness). N-Myristoylation typically mediates membrane localisation of proteins and is 
essential to the function of many. However, only a handful of proteins are experimentally 
validated as N-myristoylated in T. brucei. Here, we perform metabolic labelling with an 
alkyne-tagged myristic acid analogue, enabling the capture of lipidated proteins in insect and 
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host life stages of T. brucei. We further compare this with a longer chain palmitate analogue 
to explore the chain length-specific incorporation of fatty acids into proteins. Finally, we 
combine the alkynyl-myristate analogue with NMT inhibitors and quantitative chemical 
proteomics to globally define N-myristoylated proteins in the clinically relevant bloodstream 
form parasites. This analysis reveals five ARF family small GTPases, calpain-like proteins, 
phosphatases and many uncharacterized proteins as substrates of NMT in the parasite, 
providing a global view of the scope of this important protein modification and further 
evidence for the crucial and pleiotropic role of NMT in the cell.  
 
Keywords: Human African trypanosomiasis, N-myristoylation, chemical proteomics, click 
chemistry, protein lipidation, target validation 
Introduction 
Human African Trypanosomiasis (HAT), or African Sleeping Sickness, is a usually fatal 
tropical disease caused by unicellular eukaryotic parasites of the genus Trypanosoma brucei 
and transmitted by an insect vector. Although the number of reported cases has dropped in 
recent years,1 an estimated 21 million people are at high to moderate risk of the disease.2 In 
addition, the analogous livestock disease, Nagana, causes an estimated 3 million cattle 
deaths per year with significant economic impact.3 T. brucei gambiense, responsible for 
>98% HAT cases, causes a chronic infection in which the early stage, lasting several 
months or years, is relatively asymptomatic; later in infection, parasites cross the blood-brain 
barrier and invade the central nervous system, ultimately leading to coma and death. There 
are few treatments currently available to treat late stage HAT and all suffer from high toxicity, 
high expense or problematic delivery.4 T. brucei is transmitted primarily by the bite of an 
infected tsetse fly, which injects the metacyclic trypomastigote form of the parasite into the 
mammalian host, although mother to foetus transmission can also occur. The parasite then 
transforms into the bloodstream form (BSF) which remains extracellular in the blood stream 
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and lymph. When a tsetse fly takes a blood meal from the infected host, parasites are taken 
up and transform into procyclic forms (PCF) that multiply in the insect gut prior to 
transformation into epimastigotes, which travel to the insect salivary gland.5 The BSF is 
therefore of most interest for treatment of infection and progression of the disease, whereas 
the PCF is important for replication in the insect vector. The adaptive differences between 
BSF and PCF, and the process of differentiation, are important for druggability of BSF 
trypanosomes in the mammalian host. 
The enzyme myristoyl-CoA:protein N-myristoyltransferase (NMT) is an essential eukaryotic 
enzyme that catalyses attachment of the C14:0 fatty acid myristate from myristoyl-CoA to the 
N-terminal glycine residue of a subset of cellular proteins,6 N-Myristoylation mediates 
membrane localisation, modulates stability, or regulates protein-protein interactions, and 
NMT has been investigated as a potential drug target in HAT,7 fungal infections,8 
leishmaniases,9 malaria,10 nematodes11 and cancer.12 Structure-based design and high-
throughput screening have yielded multiple NMT inhibitor series, some with species 
selectivity.7, 13 In T. brucei, RNAi knockdown of NMT results in abnormal morphology and 
defects in endocytic trafficking.14 Trafficking defects may in part be related to loss of 
myristoylation of members of the ADP-ribosylation factor (ARF) family of small GTPases 
involved in vesicular trafficking in eukaryotes. RNAi depletion of two N-myristoylated T. 
brucei ARFs showed that the proteins are essential for viability of BSF parasites and 
revealed defects in subcellular structures such as the flagellar pocket (the site of almost all 
endo- and exocytosis), vesicles and the Golgi apparatus.15 In 2010, Frearson et al. reported 
a series of NMT inhibitors with high potency against the T. brucei enzyme, with the ability to 
cure trypanosomiasis in mice.7, 13a, 13b The phenotype of inhibitor treatment was distinct from 
RNAi knockdown of NMT but the parasite did exhibit an enlarged flagellar pocket.7 Given the 
co-translational nature of N-myristoylation, NMT inhibitors would be expected to impact 
viability of both BSF and PCF parasites, since both forms replicate; in terms of clinical 
treatment, however, targeting BSF parasites is of most interest. 
Page 10 of 38
ACS Paragon Plus Environment
ACS Infectious Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
  
Bioinformatic analyses suggest that more than 60 proteins may be N-myristoylated in T. 
brucei, resulting in the prediction that NMT inhibition will have pleiotropic effects on the 
parasite.16 There is some experimental evidence for N-myristoylation of a few parasite 
proteins: three ARFs,15a, 15b, 17 cytoskeleton-associated protein CAP5.5,18 Calflagin,19 
phosphatase PPEF,16 flagellar-calcium binding protein FCaBP (in the related parasite T. 
cruzi)20 and virulence-associated metacaspase 4 (MCA4).21 However, global 
characterisation of N-myristoylation by standard biochemical methods such as radiolabelling 
is hampered by low sensitivity, the need for specific antibodies for target proteins and the 
frequent requirement for artificial overexpression to achieve detection. We and others have 
recently made use of bioorthogonally tagged fatty acids which are metabolically incorporated 
into proteins to globally profile myristoylation and other protein lipidations in diverse 
organisms,22 including the trypanosomatid parasite Leishmania donovani, which causes 
leishmaniasis.23 Here we apply this technology to study lipidation in T. brucei, comparing 
acylated proteins in the insect (PCF) and host (BSF) life stages using a tagged analogue of 
myristate, and analysing acylation patterns with a tagged palmitate analogue. Finally, we 
quantify changes in acylation levels in the presence of NMT inhibitors, and demonstrate 
selective target engagement across the proteome through quantitative chemical proteomic 
analyses. Taken together, these data globally define NMT substrates in the key life stages of 
the parasite, and provide insight into the mechanism of action of NMT inhibitors in T. brucei. 
Results and Discussion 
Fatty acids bearing terminal alkyne or azide modifications are known to be tolerated by the 
cellular machinery in diverse systems and incorporated into acylated proteins.22a Our 
approach uses myristic acid analogue YnMyr (Fig. 1a), the coenzyme-A analogue of which is 
accepted as a substrate by NMTs, and which we have previously shown is incorporated into 
N-myristoylated proteins in Plasmodium falciparum,10 Leishmania donovani,23 human cancer 
cells,12 virus infected cells24 and zebrafish embryos.25 After cell lysis, alkyne-tagged proteins 
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are captured by a click reaction, the copper-catalysed cycloaddition of an alkyne and azide 
(CuAAC), appending a variety of groups such as a fluorophore for visualisation and/or biotin 
for affinity pull-down.26 Enriched proteins are then subject to tryptic digest and shotgun LC-
MS/MS analysis for proteomic identification (Fig. 1a). 
YnMyr labels proteins in Trypanosoma brucei 
To investigate whether YnMyr can be used to label proteins in T. brucei, cultures of PCF 
parasites were incubated for 18 hours with 100 µM YnMyr or myristic acid (Myr) control. 
Following cell lysis, tagged proteins were ligated to biotin and TAMRA functionalised reagent 
AzTB (Supp. Fig. S1) via CuAAC and visualised by in-gel fluorescence following separation 
by SDS-PAGE. In addition to multiple discrete bands, two diffuse bands were observed 
between 20 and 40 kDa (Fig. 1b), which could be removed by chloroform-methanol 
precipitation or base treatment of proteins after CuAAC. Trypanosomatid parasites are 
abundant in complex glycolipids, and PCF T. brucei possess a family of surface proteins, the 
procyclins, which bear a glycan elaborated glycosylphosphatidylinositol (GPI)-anchor near 
their C-terminus and in some cases N-glycosylation in the N-terminal domain27. When 
separated by SDS-PAGE, procyclins migrate as two polydisperse bands at ~30 and 40 kDa, 
and can be radiolabelled with 3H-myristate.28 Treatment of YnMyr-labelled PCF samples with 
pronase shifted a proportion of the diffuse bands to lower molecular weight and completely 
removed the majority of labelling (Fig. 1c), consistent with the discrete bands corresponding 
to proteins and the diffuse bands corresponding to the partially protease-resistant procyclins. 
Alternatively, the bands may correspond to other glycolipid components, such as free poly-
N-glycosylated GPIs that are also present on the surface of T. brucei PCF.28a 
Having established that YnMyr could label proteins in the procyclic insect stage-form of T. 
brucei, we focused on host stage parasites. Cultured BSF cells were incubated with 100 µM 
YnMyr or Myr for 4, 8 or 18 hours and lysates processed as described above. Labelling 
intensity increased from 4 to 8 hours but decreased again at 18 hours, at which time point 
YnMyr-related toxicity was also observed (Figs. 2a & 2b; Supp. Fig. S3); parasites exhibited 
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the so-called “Big Eye” phenotype, which is characterised by an enlarged flagellar pocket. 
This phenotype is the result of a block in receptor-mediated endocytosis, and has previously 
been described following RNAi knockdown of clathrin heavy chain29 and the small GTPase 
ARF1.15b Consistent with our results, YnMyr was previously shown to be moderately toxic to 
T. brucei in a study seeking to identify inhibitors of VSG (Variant Surface Glycoprotein) GPI 
myristoylation.30 The VSG coats the surface of BSF T. brucei and is unusual in incorporating 
specifically diacyl-myristate into its GPI-anchor31. This feature is unique to T. brucei BSF, 
and multiple cellular pathways have evolved to ensure that myristate alone is incorporated. 
We hypothesise that the observed YnMyr toxicity is related to disruption of the VSG 
myristate pathway, and an 8 hour tagging step was therefore used in subsequent 
experiments to circumvent YnMyr-related toxicity, and focus analysis on N-myristoylated 
proteins. 
A prominent band between 50 and 75 kDa showed sensitivity to treatment with strong base 
(NaOH; Fig. 2c, Supp. Fig. S4), indicating ester-linked YnMyr and consistent with 
incorporation of the probe into the GPI-anchor of the VSG, as expected. We have previously 
observed significant incorporation of tagged fatty acids into GPI-anchored proteins in the 
malaria parasite Plasmodium falciparum.10 The majority of other bands were insensitive to 
base-treatment, implying amide-linked YnMyr. Azido-myristate mimetic AzMyr gave very 
similar labelling to YnMyr, as expected, whereas longer chain palmitate analogue YnPal 
gave a distinct pattern (Figs. 2d and 2e). These data are consistent with incorporation of 
tagged fatty acids into proteins by chain-length specific acyltransferases such as NMT and 
palmitoylacyltransferases (PATs). 
Proteomic identification of YnMyr labelled proteins in T. brucei 
We have previously shown that YnMyr is incorporated into putative N-myristoylated protein 
ARL6 via labelling of this protein after immunoprecipitation (IP).17 However, the IP method 
relies on the availability of an antibody to the protein of interest and has very low throughput. 
To carry out global identification of the proteins labelled in BSF and PCF parasites, tagged 
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proteins were ligated to AzTB and enriched by pull-down onto NeutrAvidin-coated resin 
through the biotin affinity label (Supp. Fig. S5). Bead-bound proteins were subject to tryptic 
digest and peptides analysed by LC-MS/MS. Each sample set consisted of a YnMyr sample 
and Myr control, prepared in parallel. Raw data were searched using MaxQuant32 and a 
database of the T. brucei TREU 927 reference strain (TriTrypDB33). In-gel fluorescence 
analysis suggested that VSG was also labelled with YnMyr and the VSG variant is strain-
specific. Initial BSF experimental data were therefore also searched against the T. brucei 
Lister strain 427, identifying VSG variant Tb427.BES40.22; this protein sequence was 
appended to the TREU 927 FASTA file for all subsequent searches. Data were analysed 
using label-free quantification (LFQ), a technique that normalises intensity measurements to 
enable comparison between different LC-MS/MS runs, in MaxQuant (“MaxLFQ”).34 After 
Log2 transformation of intensities, data were filtered to retain only proteins present in several 
replicates, missing values were imputed from a normal distribution to mimic values at the 
limit of detection, and permutation-corrected two-sample t-tests used to assess proteins 
significantly enriched in YnMyr samples over Myr controls (see Methods). A caveat to this 
analytical workflow is that proteins detected in multiple YnMyr samples but with low intensity 
will be assigned as non-significant even if they are absent from Myr controls because their 
intensity is too close to background; many of these proteins could be genuine hits but of low 
abundance. 
In BSF experiments, proteins were filtered to retain only those present in at least 3 out of 4 
replicates and in biological duplicate, resulting in 101 significantly enriched proteins in YnMyr 
samples (Fig. 3a, Supp. Table S1). Of these, 46 (46%) are likely to carry an N-terminal 
glycine implied by an MG motif at the N-terminus, which is thought to be a requirement for 
NMT-dependent myristoylation.35 In PCF experiments, proteins were filtered to retain only 
those present in at least 4 out of the 6 technical replicates and in biological duplicate, 
identifying 91 proteins as significantly enriched in YnMyr samples (Fig. 3b, Supp. Table S2); 
again, roughly half of these proteins have an N-terminal MG motif. 
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Non-MG proteins highly enriched in YnMyr samples include glycosylphosphatidylinositol-
specific phospholipase C (GPI-PLC), a protein that is S-myristoylated,36 in BSF samples, 
and MSP-B (a homologue of GPI-anchored Leishmania GP63 surface protease), procyclic 
form surface phosphoprotein (PSSA-2) and p-glycoprotein-A in PCF parasites. The GPI-
anchored VSG was also detected in BSF samples and was enriched in YnMyr experiments 
compared to controls. Proteins previously shown to be N-myristoylated in T. brucei or related 
species included flagellar calcium binding protein (FCaBP, shown to be N-myristoylated in T. 
cruzi),20 cytoskeleton-associated protein CAP5.5,18 the proteasome regulatory ATPase 
subunit 2 (RPT2), which is known to be N-myristoylated in many eukaryotes,37 a 
phosphatase of the PPEF family,16 and a GRASP homologue (acylated in other protozoan 
parasites38). Metacaspase 4 (MCA4), previously shown to be palmitoylated at a cysteine 
residue proximal to a likely N-myristoylation site, was also identified, principally in BSF 
samples; this pseudopeptidase is an important virulence factor in Tb infection.21 Several 
ARF/ARLs, a well-studied family of N-myristoylated small GTPases, were also identified 
across the datasets: these included Tb927.7.6230, now called ARF3 (GeneDB) but 
previously known as ARL1, and shown to be both N-myristoylated and essential to survival 
of BSF T. brucei.15a, 15c ARL6 (Tb927.8.5060), which we showed previously to be tagged with 
YnMyr in T. brucei using immunoprecipitation with an ARL6 specific antibody,17 was a 
significant hit identified in both BSF and PCF parasites. 
In initial analyses using AzTB as capture reagent, no YnMyr-modified peptides were 
identified; this is unsurprising since the biotinylated peptide should remain partly anchored to 
the resin and the large TAMRA-containing label hinders detection by LC-MS/MS. We 
recently reported a series of related reagents incorporating a trypsin cleavage site between 
the TAMRA/biotin moieties and the azide capture group (Fig. 3b);25 these reagents enabled 
identification of YnMyr-tagged peptides in the malaria parasite P. falciparum,10 human 
cancer cells,12 zebrafish25 and Leishmania parasites.23 In the current study we used AzRTB 
and AzRB (Supp. Fig. S1), which both incorporate an arginine trypsin cleavage site and 
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biotin, with AzRTB also featuring a TAMRA fluorophore. Searches were carried out with the 
additional mass fragment as a variable modification on any amino acid at a peptide N-
terminus and data filtered to retain only those identifications meeting a stringent score 
threshold, as established in our previous studies25 (see Methods). Sixty five identified 
modification sites across BSF and PCF samples were matched to 56 discrete proteins; 
peptides differently modified by methionine oxidation or with different lengths due to missed 
cleavages can derive from the same protein sequence (Supp. Table S3; see Supp. Fig. S6 
for examples of assigned modified peptide spectra and Supp. Data file for all spectra). Out of 
these 65 peptides only three lacked an N-terminal glycine, and corresponded to proteins for 
which no other peptides were identified; therefore these are likely to be false positive 
identifications. When AzRTB was used to capture and enrich tagged proteins, 18 YnMyr-
modified peptides (17 proteins) were detected in T. brucei PCF samples. AzRB, however, 
resulted in more identifications, with 30 modified N-terminal glycines detected in PCF and 26 
in BSF samples. Sixteen YnMyr modified N-terminal glycines were detected independently 
with both AzRTB and AzRB; these reagents result in remnants on the modified peptide that 
are slightly different in mass (by one methylene unit), providing orthogonal evidence for 
modification of these peptides. 
BSF and PCF parasites are adapted to very different environments, and the identification of 
stage-specific proteins expressed specifically in the insect vector or the host is an ongoing 
area of research.39 Comparison of YnMyr LFQ intensities of hits (defined as proteins 
identified as significantly enriched over Myr controls in one or both life stages) by t-test 
revealed that a subset of non-MG and MG proteins were differentially detected in one life 
stage over the other (Fig. 4; Supp. Table S4). The data are in good agreement with existing 
studies. The ratio of BSF/PCF YnMyr intensities for hits was plotted against the ratio from a 
published dataset where SILAC (stable isotope labelling by amino acids in cell culture) 
quantitative proteomics was used to compare the two life stages (Butter et al.39): pleasingly, 
for the 59 proteins quantified by both studies (roughly half of the LFQ hits in our 
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comparison), the correlation was high (Pearson 0.87; Fig. 4b). Our data are also in similarly 
good agreement with an earlier SILAC-based study (Urbaniak et al.40) (Pearson correlation 
0.83; Supp. Fig. S7). These high correlations also show that, in most cases, YnMyr labelling 
tracks protein abundance. 
As expected, specific cell surface proteins such as GPI-PLC and VSG were prominent in 
BSF samples, whereas MSP-B and PSSA-2 were found in PCF samples, consistent with the 
large changes that occur to the parasite’s surface coat. Functional analysis of stage-
enriched MG motif proteins revealed several hits in the calpain family of cysteine peptidases, 
two protein phosphatases with different stage-specificities, and proteins involved in 
intracellular transport: phosphoinositide-specific phospholipase C and receptor adenylate 
cyclase (GRESAG4)41 in PCF parasites and ARL1B enriched in BSF parasites (Fig. 4c). 
Calpains are calcium-dependent cysteine peptidases and T. brucei possesses an expanded 
family of calpain-like proteins, some of which have apparently no proteolytic activity but are 
targeted lipidation or other signals to different subcellular locations.42 Although the functions 
of these proteins are largely unknown, they have been hypothesised to play regulatory roles, 
for example in cytoskeletal remodelling in the case of CAP5.5,18 or in virulence in the 
mammalian host in the case of MCA4.21 Given the widespread differential phosphorylation of 
BSF and PCF T. brucei,43 the identified stage-enriched lipidated phosphatases could also be 
particularly interesting for future studies; for example, a recent analysis of two N-
myristoylated phosphatases demonstrated their importance at specific stages of 
development in the malaria parasite.44 Thirteen MG proteins currently of unknown function 
were also enriched in one of the two stages. Interestingly, 12 lipidated proteins significantly 
enriched in our PCF dataset were found to be upregulated early in differentiation from BSF 
to PCF parasites in a recent proteomic study by Dejung et al. (Supp. Fig. S7).45 Other 
interesting hits are ARF protein ARLB, and calpain-like protein Tb927.1.2230, both enriched 
in our BSF data and identified as transiently upregulated during differentiation by Dejung et 
al., suggestive of roles in the differentiation process. Overall, our data show that lipidated 
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proteins involved in carbohydrate metabolism, phosphorylation processes, small molecule, 
ion and protein transport, and signal transduction vary between BSF and PCF parasites 
(Supp. Fig. S8), consistent with the significant changes to cell structure and metabolism that 
accompany adaptation of the cell to its different host environments. 
Proteomic identification of YnPal labelled proteins in T. brucei 
As discussed above, GPI-anchored proteins and glycoconjugates are prevalent in T. brucei 
and these are known to incorporate fatty acyl chains of varying lengths. In addition, fatty 
acids can be incorporated into proteins on cysteine side chains; S-acylation with the 16-
carbon fatty acid palmitate is a common modification across eukaryotes, including protozoan 
parasites.46 In contrast to the high specificity of NMT for myristoylation,6  S-acylation 
enzymes and pathways have been shown to be promiscuous in accepting fatty acid 
analogues with a variety of chain lengths – in mammalian cells at least.47 In an additional 
layer of complexity, some proteins are dually acylated, being N-myristoylated at the N-
terminal glycine and S-acylated with palmitate on a nearby cysteine residue.46 Furthermore, 
T. brucei is known to metabolize long chain fatty acids to meet its needs in different life 
stages and culture conditions,48 although whether alkyne-tagged analogues would also be 
substrates for these metabolic enzymes is not known. 
To provide additional insight into whether YnMyr was also incorporated into S-palmitoylation 
sites and to establish a broader picture of lipidation in T. brucei, longer chain palmitate 
analogue YnPal (Fig. 2d) was incubated with BSF parasites at 100 µM for 4, 8 or 18 hours 
and samples processed as before. In-gel fluorescence analysis revealed a distinct band 
pattern for the two analogues (Fig. 5a). Interestingly, in contrast to YnMyr, YnPal was not 
visibly toxic to parasites and labelling intensity continued to increase slightly up to 18 hours 
(Supp. Fig. S4). Similar to YnMyr, YnPal was also incorporated into a base-sensitive band at 
~60 kDa, although to a much lesser extent (Fig. 5a). YnPal proteins were enriched and 
analysed by LC-MS/MS as described above, and palmitic acid (Pal) controls were run in 
parallel. Results were filtered to retain only those in at least two of the three replicates and 
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data analysed by LFQ (Supp. Fig. S9). This YnPal dataset was compared to the YnMyr BSF 
dataset and also cross-compared with a dataset of potential palmitoylated proteins identified 
by Emmer et al.49 in T. brucei PCF using acyl-biotin exchange chemistry (ABE) (Supp. Table 
S5). ABE is an approach complementary to click chemistry for palmitoyl-protein discovery, 
and identifies proteins that bear hydroxylamine-labile linkages at cysteine residues. Protein 
hits were then categorised in the following way: 1. N-terminal glycine (MG) motif plus 
detection in the experiments of Emmer et al.; 2. Detection by Emmer et al. but no MG motif; 
3. MG proteins found in YnMyr datasets only; 4. Other MG motif proteins; 5. Others (Fig. 5b). 
YnMyr and YnPal intensities of hits, defined as proteins significant in one or both datasets 
and/or with direct detection of the N-terminal YnMyr modified peptide, were compared by t-
test (Fig. 5b). A high degree of overlap was observed between YnMyr and YnPal datasets: 
out of 134 protein hits, only 3 were exclusive to YnPal samples and 15 to YnMyr samples. 
Most MG hits were identified in either YnMyr alone (15 proteins), or in both datasets (32 
proteins), whereas non-MG hits also identified by Emmer et al. were mostly enriched in 
YnPal samples compared to YnMyr, as expected (Fig. 5b). MG proteins detected as S-
acylated by Emmer et al. also identified in the current study include FCaBP, PPEF and two 
calpain-like proteins with homology to Leishmania small myristoylated protein 1 (SMP-1), 
Tb927.1.2230 and Tb927.1.2260; there is published evidence for the S-acylation of these 
proteins on cysteines proximal to the N-terminal myristoylation site.16, 20, 50 LFQ analyses also 
revealed enrichment of known S-palmitoylated protein MCA4.21 Interestingly, other members 
of this family (MCA3 & MCA1) were also YnPal-enriched hits, suggesting that these 
interesting pseudoproteases may be S-acylated. Around 70 proteins lacking an MG motif 
and identified as YnPal hits here were not found by Emmer et al., likely due to stage-specific 
differences in the proteome (insect stage PCF parasites in Emmer et al., and human stage 
BSF cultures in the present study), and may also reflect the complementarity of ABE and 
CuAAC-based chemical proteomics for palmitoylated proteome analysis.  
Page 19 of 38
ACS Paragon Plus Environment
ACS Infectious Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
  
Proteins in the ARF/ARL family are not generally dually acylated, and the large majority were 
indeed identified only in YnMyr analyses. An interesting exception is the ARF protein 
Tb927.9.13650 (and Tb927.9.13680, differing by just one amino acid), which was detected in 
YnPal analyses, and contains a cysteine strongly predicted to be palmitoylated (CSS-Palm; 
Supp. Table S5).51 Consistent with gel-based results (Fig. 5a), the VSG was also enriched in 
YnPal samples (Supp. Table S5), albeit to a lesser extent than with YnMyr. Although 
previous data indicate that  myristate is specifically incorporated into the final GPI-anchor of 
this protein, intermediates in the GPI-anchor remodelling process contain longer chain fatty 
acids, including potentially stearate (C18:0)31, 52 Alternatively, there are other examples of 
variable lipid labelling in T. brucei, with evidence for promiscuous incorporation and 
metabolism prior to incorporation of lipids. For example, the S-acylated protein 
glycosylphosphatidylinositol-specific phospholipase C (GPI-PLC), which is responsible for 
processing the GPI anchor of VSG and other substrates, can be radiolabelled with myristate, 
palmitate or stearate;36  consistent with this, GPI-PLC was detected with almost equal 
enrichment in our YnMyr and YnPal analyses. In addition, labelling with either [3H]-myristate 
or [3H]-palmitate results in both myristate and palmitate being present on GPI-PLC, 
suggesting that trypanosomes can interconvert these fatty acids. Indeed, at least in some 
culture conditions, myristate is readily chain elongated in T. brucei to palmitate and 
stearate.53 It is conceivable that YnMyr and YnPal are processed by chain 
elongation/reduction by the trypanosome fatty acid biosynthetic machinery and incorporated 
into the VSG and other proteins; since processing occurs at the carboxyl end of the lipid, this 
would be expected to conserve the alkyne tag. Further work will be required to explore this 
possibility. 
In summary, approximately 100 YnPal tagged targets have been identified here, including 
both S-acylated and GPI-anchored proteins. 
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Chemical knockdown of NMT 
NMT has been validated pre-clinically as a drug target in T. brucei BSF via RNAi knockdown 
and chemical inhibition of the enzyme, and target engagement of inhibitor with NMT inside 
parasites was demonstrated through the reduction of protein radiolabelling with [3H]-myristic 
acid following treatment with a T. brucei NMT inhibitor (NMTi).7 Azido-myristate has also 
been used to demonstrate that NMTi reduces tagging in the related organism Trypanosoma 
cruzi in a dose-dependent manner at the level of in-gel fluorescence,54 although tagged 
proteins were not identified. Following a strategy similar to our recent reports in human 
cells12 and Leishmania donovani,23 we aimed to use quantitative proteomics in combination 
with YnMyr and a TbNMT inhibitor to provide orthogonal evidence for the identify of NMT 
substrates, whilst simultaneously defining a set of NMT substrates that may mediate the 
phenotypes observed on inhibition. 
TbNMT inhibitor 17 (Fig. 6a) was co-incubated with YnMyr in BSF parasites at 
concentrations ranging from 5 to 100 nM a dose-dependent drop in labelling of most bands 
was observed, with the notable exception of the VSG, consistent with target engagement in 
the parasite (Fig. 6b). Inhibitor 1 is reported to have an EC50 of 2 nM on BSF parasites and 
sub-nM IC50 against TbNMT, and is effective in eliminating parasites in a mouse model of 
trypanosomiasis.7 A small panel of analogues of 1,13a, 55 with varying potency against TbNMT 
(compounds 2-4, Fig. 6a), was analysed using YnMyr tagging. In all cases the same trend 
towards decreased labelling was observed, with the VSG band remaining largely unaffected 
by NMT inhibition (Supp Fig S10). Following base treatment, quantification of the decrease 
in fluorescence intensity suggested intracellular inhibition of N-myristoylation with TC50 
(concentration of compound resulting in a 50% decrease in tagging) in the low nM range for 
1, 3 and 4, and in the low µM range for 2, in line with the measured enzyme potencies for 
these compounds (Fig. 6a,c). These data are consistent with the on-target action of these 
inhibitors in parasites, and provides further evidence that the majority of base treatment-
insensitive YnMyr labelling in Tb BSF is NMT-dependent. 
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In order to identify proteins for which acylation levels were selectively affected by NMT 
inhibition, YnMyr tagged BSF parasites were treated with 1 at 5, 10 or 100 nM, or 2 at 1, 5 or 
20 µM, concentrations designed to probe the range of tagging reduction observed in gels for 
more and less potent examples of TbNMT inhibitors. The resulting samples (16 total, 
including replicates) were subject to CuAAC, base-treatment to remove GPI-anchored 
proteins, enrichment and LC-MS/MS analysis; Myr controls were processed in parallel 
(Supp. Fig. S11). Data were analysed by MaxLFQ34 and proteins quantified in both no-
inhibitor replicates were selected for analysis of enrichment levels over background 
(YnMyr/Myr) and response to inhibitor (Supp. Table S6). A subset of MG proteins, including 
almost all proteins identified as having a YnMyr-modified N-terminus, were enriched over 
Myr controls, and this enrichment reduced in response to the highest concentrations of 
inhibitor (100 nM 1 and 20 µM 2) (Fig. 7a). Examination of enrichment ratios (enrichment 
over Myr controls, normalised to samples with no inhibitor; see Methods for detailed 
description of data processing and analysis) revealed 54 proteins that responded robustly to 
the highest concentrations of both inhibitors 1 & 2. Of this subset, only one did not contain 
an N-terminal glycine. Hierarchical clustering was performed on the 54 putative hits and four 
clusters of response were defined (Supp. Fig. S12); protein responses were further 
examined by plotting enrichment relative to concentration of inhibitor (Table 1, Fig. 7b and 
Supp. Fig. S13). The sole non-MG protein (Tb927.8.2250, annotated as a putative tRNA 
ligase) only responded to the highest concentration of NMT inhibitor (Fig. 7c) and may be a 
downstream or low affinity off-target of the inhibitor. Interestingly, this protein was identified 
by Emmer et al. as S-acylated in PCF parasites.49 The remaining 53 hits, classed as ‘high 
confidence’, showed a variety of robust dose-responses; a range of substrate sensitivity 
towards NMT inhibition was also observed in human cells and Leishmania parasites.12, 23 
In addition to the 53 high confidence hits, a further 10 proteins showed a weaker dose-
response to NMT inhibitors, but this group included 7 proteins in which the YnMyr-modified 
peptide was identified on the N-terminal glycine. The 10 proteins were thus assigned as 
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‘medium confidence’ hits, and include FCaBP (previously identified as N-myristoylated)20 
and putative N-myristoylated protein MCA4.21 The remaining MG proteins, which neither 
responded in a dose-responsive manner to NMT inhibitors nor had an identified N-terminal 
modified glycine, were classed as non-substrates, and included ribosomal proteins and 
others not expected to be myristoylated. Notably, two widely used bioinformatics tools35, 56 
for prediction of whether a protein is a likely NMT substrate disagreed for 18 of the high 
confidence hits identified here and predicted no myristoylation for an additional 7 (Supp. Fig. 
S14; Table S7). This is not necessarily surprising given that these tools were trained on 
datasets from other organisms, and highlights the value of experimentally identifying NMT 
substrates. 
Proteins for which the level of YnMyr tagging responded in a dose-dependent manner to 
both NMT inhibitors are highly likely to be NMT substrates (i.e. high confidence hits). These 
included Golgi reassembly stacking protein (GRASP), proteasome regulatory ATPase 
subunit 2 (RPT2), five members of the ADP-ribosylation factor (ARF) family of GTPases, 
four proteins involved in fatty acyl CoA synthesis, four phosphatases (including PPEF), 
calpain-like proteins and many proteins of unknown function. Fifty percent of high confidence 
NMT substrate proteins identified here are associated with a loss of fitness in RNAi 
knockdown experiments in different life stages or conditions (Supp. Table S6; Alsford et al.57; 
and data extracted from TriTrypDB33), and merit further investigation as substrates with the 
potential to mediate the antiparasitic effects of TbNMT inhibitors. 
Conclusions 
Here we have used chemical proteomics and a suite of chemical tools – bioorthogonally 
tagged fatty acid analogues, CuAAC capture reagents with cleavable moieties for 
myristoylation site identification, and N-myristoyltransferase inhibitors – to explore protein 
lipidation in the protozoan pathogen T. brucei. We identify lipidated proteins in bloodstream 
and procyclic form parasites, and report the first comparative quantitative analysis of stage-
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enriched lipidated proteins. We also show that alkyne palmitate analogue YnPal can be used 
to tag S-acylated proteins in T. brucei; this analogue should prove a useful tool for further 
exploring palmitoylacyltransferase enzymes as potential drug targets. Furthermore, as we 
have previously shown in other organisms,12, 23 quantitative chemical proteomics combined 
with well-characterised enzyme inhibitors proved to be a powerful combination for clearly 
defining NMT substrates amid the complexity of metabolic tagging. The N-myristoylated 
proteins identified here are involved in many important cellular processes, and our datasets 
provide a rich resource for future investigation of the complex and pleiotropic impact of NMT 
inhibition in T. brucei. Data are available via ProteomeXchange with identifier PXD004053. 
Finally, tagging of proteins by other mechanisms, for example incorporation of YnMyr into 
the GPI-anchor of the VSG as shown here, suggests that such analogues may also be 
useful tools for probing the GPI-anchor and lipid metabolism pathways in trypanosomes. 
Methods 
Chemical tools 
The following chemical tools were synthesized as described previously: YnMyr, YnPal and 
AzTB;58 AzMyr and YnTB;26 inhibitors 1 and 2;12 AzRB and AzRTB.25 Myristic and palmitic 
acids, and all other chemicals were purchased. 
Parasite culture 
The T. brucei brucei BSF strain Lister 427 was maintained in vitro at 37 °C with 5% CO2 in 
HMI-9 medium containing 2 µg/mL Geneticin (Invitrogen).59 The Lister 427 strain is 
monomorphic and has lost the ability to differentiate from long-slender trypomastigotes into 
the short-stumpy form. Cells were routinely maintained at a density less than 1 x 106/mL. 
The T. brucei brucei procyclic strain 449 was maintained in vitro at 26 °C in SDM-79 medium 
containing 25 µg/mL phleomycin.59 Cells were routinely maintained at a density less than 1.5 
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x 107/mL. All culture media contained 10% tetracycline-free fetal bovine serum (Autogen 
Bioclear). 
Metabolic tagging experiments 
Parasites were metabolically labelled by the addition of 100 µM myristic acid or 
YnMyr to T. brucei BSF (set up at 2.5×105/mL in HMI-9 medium the previous day) or PCF 
(5 x 106/ml in SDM-79). Cells were then grown for 8 h at 37 °C with 5% CO2 (BSF) or for 18 
h at 26 °C (PCF) before harvesting. Parasites were lysed in ice-cold RIPA buffer (50 mM Tris 
pH 7.4, 1% NP-40, 1% sodium deoxycholate, 150 mM NaCl, 0.5% SDS and 1× Complete 
EDTA-free protease inhibitor cocktail (Roche)), sonicated 3× 10 sec at amplitude 45 with 1 
min intervals on ice), then centrifuged at 16,000 g for 30 min at 4 °C. For inhibition 
experiments, parasites were pre-treated for 1 h with inhibitors 1-4 at indicated concentrations 
and then Myr or YnMyr probe added for the remaining labelling time (8 h for BSF, 18 h for 
PCF). 
CuAAC labelling, pull-down and gel-based analysis 
CuAAC chemistry, pull-down and gel-based analysis was performed as described 
previously.23 In brief, proteins were precipitated, resuspended, and CuAAC performed as 
described.26 Proteins were enriched on Streptavidin or Neutravidin-coated beads. 
Visualisation was carried out using an Ettan™ DIGE Imager (Amersham Biosciences) - Cy3 
channel to detect TAMRA-labelled proteins. 
Proteomic sample preparation and analysis 
Sample preparation for proteomics analysis and LC-MS/MS was carried out as described 
previously (also detailed in Supporting Information).12 
Data processing: general comments 
The data were processed with MaxQuant version 1.5.3.8, and the peptides were identified 
from the MS/MS spectra searched against TriTrypDB-25 T. brucei TREU927 database using 
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the Andromeda search engine. The VSG protein for the 427 strain was not present in this 
database and so initial experiments B1 and B2 (see below) were searched against the T. 
brucei Lister strain 427. The TriTrypDB sequence for the identified VSG variant 
Tb427.BES40.22 was appended to the FASTA file. Cysteine carbamidomethylation was 
used as a fixed modification, and methionine oxidation and N-terminal acetylation as variable 
modifications. The false discovery rate was set to 0.01 for peptides, proteins and sites. Other 
parameters were used as pre-set in the software. “Unique and razor peptides” mode was 
selected to allow for protein grouping; this calculates ratios from unique and razor peptides 
(razor peptides are uniquely assigned to protein groups and not to individual proteins). LFQ 
experiments in MaxQuant were performed using the built-in label-free quantification 
algorithm (MaxLFQ).34 Data were elaborated using Perseus version 1.5.0.31, Excel and 
Graphpad Prism. The data have been deposited to the ProteomeXchange with identifier 
PXD004053. 
Data analysis 
Enrichment-LC-MS/MS experimental design for YnMyr samples (for each experiment, both 
Myr and YnMyr samples were processed): 
Expt Biological 
sample 
Reagent  Expt Biological 
sample 
Reagent 
B1 BSF1 AzTB  P1 PCF1 AzTB 
B2 BSF2 AzTB  P2 PCF2 AzTB 
B3 BSF2 AzTB  P3 PCF1 AzTB 
B4 BSF2 AzRB  P4 PCF2 AzTB 
    P5 PCF2 AzRTB 
    P6 PCF1 AzRB 
 
BSF analysis. Dataset: experiments B1-4. For the search, “Match between runs” was 
enabled within parameter groups but not between them (parameter groups: Myr, YnMyr). 
Replicates were grouped together (groups: Myr, YnMyr). The YnMyr protein group was 
filtered to require three valid values across the four replicates and then filtered to retain only 
those proteins present in biological duplicate (present in both experiments B1 and B2/3/4). 
Label free intensities were logarithmized (base 2) and empty values were imputed with 
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random numbers from a normal distribution, whose mean and standard deviation were 
chosen to simulate low abundance values close to noise level (impute criteria: width 0.1 and 
down shift 1.8; imputation for each sample individually). A modified t-test with permutation 
based FDR statistics was applied (250 permutations; FDR 0.001; s0 1) to compare Myr and 
YnMyr groups. 
PCF analysis. Dataset: experiments P1-6. For the search, “Match between runs” was 
enabled within parameter groups but not between them (parameter groups: Myr, YnMyr). 
Replicates were grouped together (groups: Myr, YnMyr). The YnMyr protein group was 
filtered to require three valid values across the four replicates and then filtered to retain only 
those proteins present in biological duplicate (present in both experiments P1/3/6 and 
P2/4/5). Label free intensities were logarithmized (base 2) and empty values were imputed 
with random numbers from a normal distribution (impute criteria: width 0.1 and down shift 
1.8; imputation for each sample individually). A modified two-sample two-sided t-test with 
permutation based FDR statistics was applied (250 permutations; FDR 0.001; s0 1) to 
compare Myr and YnMyr groups. 
BSF and PCF comparisons. Dataset: experiments B1-4 and P1-6. Datasets were searched 
together with MaxLFQ. Data were filtered for at least three valid values in at least one group 
(groups: BSF_Myr, BSF_YnMyr, PCF_Myr, PCF_YnMyr). The total dataset was filtered to 
require 3 BSF_YnMyr or 4 PCF_YnMyr valid values, then cross-referenced with individual 
analyses (described above) to retain hits only. Missing values were imputed (impute criteria: 
width 0.1 and down shift 1.8) and two-sample t-tests used to compare YnMyr intensities 
across BSF and PCF (250 permutations; FDR 0.01, s0 2). Data were elaborated in Excel 
and compared to literature datasets.39-40, 45 
Modified peptide analyses. Datasets: experiments B4, P5, P6. MaxQuant searches were 
carried out as above with the following modifications: the minimum peptide length was 
reduced to 5. This is because the N-terminus of NMT substrates often contains a lysine 
residue,35 resulting in short N-terminal tryptic peptides. Modification with YnMyr and the 
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expected portion of AzRB or AzRTB was specified as a variable modification. YnMyr-
modified peptide matches were filtered to retain only those with a score (the Andromeda 
score for the best identified among the MS/MS spectra) >40 and delta score (the score 
difference to the second best peptide identification) >20. 
YnPal and YnMyr comparisons (BSF). Dataset: YnMyr experiments B2-4; YnPal: three 
technical repeats (A-C, processing from the lysate stage) of one biological sample (YnPal 
and Pal samples). Data were searched together by MaxLFQ. Data were filtered for at least 
two valid values in at least one group (groups: Myr, YnMyr, Pal, YnPal). Label free intensities 
were logarithmized (base 2). YnMyr and YnPal datasets were then analysed separately: 
filtered (at least 2 valid values in either Myr or YnMyr; at least 2 valid values in either Pal or 
YnPal), missing values were imputed (impute criteria: width 0.1 and down shift 1.8) and two-
sample t-tests used to define potential hits in each case (250 permutations; FDR 0.05, s0 1). 
The total dataset was then cross-referenced with individual analyses to retain hits only (t-test 
significant proteins and those where modified peptide was identified). Missing values were 
imputed (impute criteria: width 0.1 and down shift 1.8, across total dataset) and two-sample 
t-tests used to compare YnMyr and YnPal intensities (250 permutations; FDR 0.05, s0 1). 
Data were elaborated in Excel and compared to a literature dataset.49 
YnMyr tagging in the presence of NMT inhibitors (BSF). Groups (conditions): YnMyr, 
Myr, 5 nM 1, 10 nM 1, 100 nM 1, 1 µM 2, 5 µM 2, 20 µM 2. All samples were prepared and 
processed in duplicate (technical replicates A and B from the lysate stage). The ‘Match 
between runs’ option (time window 0.7 minutes, alignment time window 20 min) in Maxquant 
was enabled during the searches. Data were grouped and filtered to retain only those 
proteins present in both YnMyr replicates. The mean of the technical replicates was 
calculated and then missing values were imputed from a normal distribution (width 0.1, 
downshift 1.8; separately for each dataset). Response ratios (YnMyr/(YnMyr + inhibitor)) and 
enrichment ratios ((YnMyr + inhibitor)/Myr) were calculated and enrichment ratios 
subsequently normalised to YnMyr only (no inhibitor) to compare between proteins and 
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across conditions. Proteins with -Log2((YnMyr + inhibitor)/Myr)>2 (response ratio>2) for 100 
nM 1 and 20 µM 2 were selected as potential hits. These hits were further analysed by 
plotting the dose-response curves (normalized enrichment ratios). 
Supporting information 
Additional Figures S1-14; additional Tables S1-7; Supporting Data File (modified peptide 
spectra); detailed experimental protocols for CuAAC, pull-down, gel-based analysis, 
preparation and measurement of proteomic samples, and bioinformatics analysis. This 
information is available free of charge via the Internet at http://pubs.acs.org/. 
The  mass  spectrometry  proteomics  data  have  been  deposited  to  the 
ProteomeXchange Consortium  (http://proteomecentral.proteomexchange.org) via the 
PRIDE partner repository60 with the dataset identifier PXD004053. 
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Table 1. List of high and medium confidence N-myristoylated protein hits. Proteins were 
identified by quantitative proteomics with YnMyr in combination with NMT inhibitors. Mean 
normalised enrichment ratios (YnMyr/Myr) given and cells are colour coded based on value 
(blue=0, red=1, yellow=50 percentile). Proteins for which the YnMyr-modified N-terminus 
was detected (Mod. Pept.) and those identified as hits in PCF samples are indicated Some 
protein groups contained multiple proteins (“&others”). See also Supp. Table S6.   
 Normalised enrichment ratios     
  Inhib.1 (nM) Inhib. 2 (µM)     
Protein IDs 0 5 10 100 1 5 20 MG 
Mod. 
Pept. PCF Protein description 
High confidence hits 
Tb927.10.4930 1.00 0.76 0.77 -0.07 0.80 0.38 0.14 + +  protein phosphatase 2C 
Tb927.10.12940 1.00 0.93 0.89 0.56 1.00 0.64 0.18 + + + predicted zinc finger protein 
Tb927.11.760 1.00 0.94 0.81 0.39 1.00 0.68 0.37 + + + protein phosphatase 2C 
Tb927.7.5340 1.00 0.92 0.85 0.39 0.95 0.62 0.50 + + + uncharacterised 
Tb927.9.11870 1.00 0.46 0.24 0.12 0.54 0.17 0.23 + +  zinc finger protein 
Tb927.6.1800 1.00 0.95 0.83 0.42 0.98 0.57 0.35 + + + protein phosphatase 2C 
Tb927.6.2090 1.00 1.00 0.97 0.64 1.03 1.05 0.53 + + + pdz domain containing protein 
Tb927.9.8350 1.00 0.93 0.91 0.45 1.02 0.65 0.27 + + + uncharacterised 
Tb927.8.2280&others 1.00 0.86 0.86 0.67 0.92 0.75 0.08 + + + POMP39B,D,C 
Tb927.7.6230 1.00 0.74 0.68 -0.02 0.85 0.51 0.15 + + + ADP-ribosylation factor (ARF3) 
Tb927.9.6530 1.00 0.79 0.74 0.44 0.81 0.61 0.31 + +  uncharacterised 
Tb927.9.6170;Tb927.9.6230 1.00 0.73 0.53 0.18 0.82 0.39 -0.07 + + + uncharacterised 
Tb927.7.510;Tb11.v5.0890 1.00 0.97 0.92 0.55 0.97 0.82 0.62 + + + uncharacterised 
Tb927.7.1630 1.00 0.30 0.15 0.14 0.44 0.08 0.14 + + + uncharacterised 
Tb927.10.3260;Tb11.v5.0825 1.00 0.77 0.70 0.44 0.83 0.43 0.28 + + + Long-chain-fatty-acid--CoA ligase 5 
Tb927.1.2230 1.00 0.98 0.95 0.71 0.98 0.86 0.76 + + + calpain-like protein fragment 
Tb927.4.4360 1.00 0.85 0.78 0.63 0.86 0.77 0.60 + + + monoglyceride lipase 
Tb927.8.2070 1.00 0.87 0.77 0.61 0.88 0.70 0.46 + +  unknown (POMP39A) 
Tb927.9.13740&others 1.00 0.90 0.77 0.41 0.93 0.69 0.45 + + + ADP-ribosylation factor 
Tb927.9.4230 1.00 0.81 0.70 0.02 0.97 0.69 0.21 + + + fatty acyl CoA synthetase 4 (ACS4) 
Tb927.8.2450 1.00 0.88 0.73 0.02 0.86 0.57 0.08 + +  SNF1-related protein kinase/AMPKB 
Tb927.9.8180 1.00 0.83 0.70 0.14 0.92 0.59 0.25 + + + uncharacterised 
Tb927.9.4210;Tb11.v5.0561 1.00 0.88 0.80 0.50 0.91 0.46 0.41 + + + fatty acyl CoA synthetase 3 (ACS3) 
Tb927.1.2260 1.00 0.84 0.67 0.11 0.84 0.54 0.47 + + + calpain-like protein fragment 
Tb927.3.4590 1.00 0.62 0.52 0.31 0.74 0.46 0.20 + + uncharacterised 
Tb927.4.4570 1.00 0.84 0.74 -0.01 0.99 0.64 0.18 +  uncharacterised 
Tb927.11.3740 1.00 0.91 0.87 0.46 0.98 0.61 0.44 + 
 
+ proteasome regulatory ATPase subunit 2 (RPT2) 
Tb927.1.1500 1.00 0.96 0.92 0.62 0.98 0.75 0.58 +  uncharacterised 
Tb927.2.4280 1.00 0.89 0.91 0.38 0.93 0.75 0.05 +  kinetoplastid-specific dual specificity phosphatase 
Tb927.8.3970 1.00 0.97 0.90 0.42 1.01 0.69 0.47 + + Oxidoreductase 
Tb927.7.7240 1.00 0.92 0.99 0.49 1.00 0.85 0.60 + 
 
 leucine-rich repeat protein (LRRP) 
Tb927.10.7760 1.00 0.75 0.54 0.04 0.81 0.39 0.22 +  Uncharacterised 
Tb927.8.5060 1.00 0.56 0.45 -0.02 0.71 0.30 0.15 + + ADP-ribosylation factor 
Tb927.10.12630 1.00 0.67 0.50 0.15 0.66 0.22 0.16 + + Uncharacterised 
Tb927.11.9190 1.00 0.82 0.83 0.21 0.93 0.62 0.30 + 
 
 protein kinase 
Tb927.7.5600 1.00 0.66 0.68 -0.02 0.85 0.62 0.19 +  leucine-rich repeat protein (LRRP) 
Tb927.1.4050 1.00 0.90 0.87 0.58 0.96 0.78 0.67 + + PPEF 
Tb927.8.4570 1.00 0.95 0.83 0.47 0.97 0.77 0.15 +  Zinc finger 
Tb927.1.1420 1.00 0.86 0.86 0.10 1.08 0.32 0.21 + 
 
+ uncharacterised 
Tb927.1.5030 1.00 0.88 0.75 0.50 1.00 0.55 0.49 +  leucine-rich repeat protein (LRRP) 
Tb927.4.4580 1.00 0.90 0.92 0.50 0.99 0.84 0.61 +  uncharacterised 
Tb927.4.4550 1.00 0.83 0.79 -0.02 1.07 0.72 0.19 +  uncharacterised 
Tb927.8.7780 1.00 1.01 0.95 0.44 1.11 0.93 0.23 + 
 
 uncharacterised 
Tb927.8.4940 1.00 0.66 0.64 0.49 0.67 0.56 0.41 + + uncharacterised 
Tb927.8.7760 1.00 0.88 0.86 0.32 0.91 0.73 0.24 +  uncharacterised 
Tb927.10.6820 1.00 0.71 0.60 0.04 0.82 0.59 0.09 + + uncharacterised 
Tb927.7.550 1.00 0.91 0.81 0.41 0.94 0.69 0.24 + 
 
 WD domain, G-beta repeat 
Tb927.1.2120 1.00 0.88 0.82 0.53 0.93 0.54 0.43 + + Calpain-like protein CALP1.3 
Tb927.8.5050 1.00 0.76 0.74 0.36 0.86 0.61 0.23 +  OTU-like cysteine protease 
Tb927.11.2660 1.00 0.30 0.06 0.12 0.41 -0.01 0.26 + + Golgi reassembly stacking protein 
Tb927.9.7230 1.00 0.89 0.81 0.43 0.92 0.71 0.34 + 
 
 ADP-ribosylation factor-like protein (ARL1B) 
Tb927.9.4190 1.00 0.87 0.85 0.46 0.98 0.75 0.43 + + fatty acyl CoA syntetase 1 (ACS1) 
Tb927.9.7650 1.00 0.87 0.71 0.08 0.89 0.55 0.14 + + ADP-ribosylation factor 
Medium confidence hits            
Tb927.10.2440 1.00 1.11 1.04 0.79 1.11 1.13 0.83 + +  Metacaspase-4 (MCA4) 
Tb927.10.4770 1.00 0.83 0.68 0.62 0.77 0.83 0.19 + + + phosphatidylinositol-4-phosphate 5-kinase 
Tb927.8.8330;Tb927.4.3950 1.00 0.95 0.92 0.73 1.04 0.89 0.67 + + + CAP5.5/calpain 
Tb927.7.5250 1.00 0.75 0.84 0.78 0.88 0.68 0.66 + +  uncharacterised 
Tb927.11.2400 1.00 1.09 0.99 0.92 1.14 1.06 0.94 + +  uncharacterised 
Tb927.8.5460&others 1.00 1.11 0.98 0.78 1.22 1.01 0.74 + + + Flagellar calcium-binding protein/calflagin 
Tb927.9.2670 1.00 0.85 0.73 0.56 0.94 0.78 0.70 + + + engulfment and cell motility domain 2 (POMP3) 
Tb927.8.8020 1.00 0.85 0.82 0.76 0.82 0.84 0.75 + + monoglyceride lipase 
Tb927.10.2930 1.00 0.90 0.84 0.76 1.05 0.80 0.70 +  uncharacterised 
Tb927.11.9260 1.00 1.00 0.82 0.10 0.94 0.77 0.40 +  uncharacterised 
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Figure legends 
Figure 1: YnMyr labels proteins in T. brucei PCF parasites. a. Overview of tagging strategy. 
YnMyr or myristic acid (Myr) were added to T. brucei parasite cultures and incorporated 
metabolically into lipidated proteins. The alkyne tag was reacted by CuAAC with fluorophore 
and/or biotin functionalised azide capture reagents (Supp. Fig. S1) to allow downstream 
enrichment and analysis by proteomics and SDS-PAGE. b. Labelling with YnMyr or Myr (-) 
in PCF parasites. After 18 hr incubation with probes at 100 µM, parasites were lysed, 
proteins reacted with AzTB and separated by gel for fluorescence scanning. Samples were 
treated with NaOH or precipitated with chloroform/methanol (C/M) as indicated. c. Some 
PCF labelling is resistant to treatment with pronase. Coomassie gels are shown in Supp. Fig. 
S2. 
Figure 2: YnMyr labels proteins in T. brucei BSF parasites. a. Time-dependent metabolic 
incorporation of 100 µM YnMyr or Myr (-) in BSF parasites. b. Phenotype of YnMyr treatment 
at 18 hours in BSF. Scale bar: 10 µm. See also Supp. Fig. S3. c. NaOH treatment of lysates 
from BSF parasites incubated with YnMyr reveal labelling of a base-sensitive at ~60 kDa. d. 
Chemical structures of myristate analogues YnMyr and AzMyr, and palmitate analogue 
YnPal. e. Comparative labelling with different fatty acid analogues at 100 µM in BSF. 
Coomassie gels are shown in Supp. Fig. S2. Additional data is shown in Supp. Fig. S4. 
Figure 3: Identification of YnMyr tagged proteins in (a) BSF and (b) PCF T. brucei. Volcano 
plots showing proteins significantly enriched over background. Parasites were treated with 
Myr or YnMyr, lysates labelled by CuAAC, proteins enriched by biotin-streptavidin interaction 
and digested by trypsin for LC-MS/MS. Proteins from four (BSF) or six (PCF) replicates 
(independent sample processing from the lysate stage; includes a biological replicate in 
each case) were quantified by label-free quantification (MaxLFQ). After filtering to retain only 
those proteins present in biological duplicate and in 3/4 (BSF) or 4/6 (PCF) samples, missing 
intensities were imputed from a normal distribution chosen to mimic noise level and a 
modified t-test with permutation based FDR statistics was applied (250 permutations) to 
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compare Myr and YnMyr groups. BSF & PCF: FDR = 0.001; s0 = 1. Proteins containing an 
N-terminal glycine (MG) and those for which the YnMyr-modified peptide was identified using 
reagents AzRB or AzRTB in the respective lifestage are indicated. See also Supp. Tables 
S1&2; Table S3 for modified peptide data. 
Figure 4: Comparison of acylated proteins in two life stages of T. brucei. a. Volcano plot 
comparing YnMyr intensities of hits (defined as proteins significantly enriched over Myr 
controls in one or both life stage) by a two-sided two-sample permutation-corrected t-test 
(250 permutations; FDR 0.01, s0 2). Those proteins only identified in one life stage 
(BSF/PCF only) and N-terminal glycine-containing proteins (MG) are indicated. b. 
Comparison of relative abundance of protein hits in BSF and PCF parasites in the current 
study (LFQ quantification; ratio of YnMyr intensities is plotted) with the study of Butter et al. 
(quantification via SILAC).39 Comparison with another previously reported dataset is shown 
in Supp. Fig. S7. See also Supp. Table S4. c. Heatmap and functional classification of MG 
proteins found/enriched in one of the two stages. YnMyr intensities shown and colour-coded 
within each row. The total dataset is shown in Supp. Fig. S8. 
Figure 5: Comparison of myristate and palmitate tagging in T. brucei BSF. a. BSF parasites 
were incubated with YnMyr or YnPal (Fig. 2d) probes for 8 h and tagged proteins visualised 
by in-gel fluorescence after CuAAC. The gel was subject to treatment with NaOH and 
reimaged to identify base labile bands. b. Volcano plot comparing YnMyr and YnPal intensity 
for protein hits (significantly enriched over Myr or Pal controls). Two-sided two-sample 
permutation-corrected t-test (250 permutations; FDR 0.05, s0 1). Proteins are categorised 
and colour coded to indicate if they were identified as palmitoylated by Emmer et al. (Tb PCF 
palmitoylome), or contain an N-terminal glycine (MG). See also Supp. Fig. S9 and Supp. 
Table S5. 
Figure 6: TbNMT inhibitors dose-dependently knockdown YnMyr labelling. a. Structures of 
previously reported TbNMT inhibitors 1-4, their IC50 against TbNMT and tagging-IC50 
(concentration of compound required for 50% inhibition of tagging, TC50) calculated based 
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on fluorescent gels. b. In-gel fluorescence analysis of samples from parasites treated with 
indicated concentrations of 1 during YnMyr tagging. c. Quantification of in-gel fluorescence 
signal from NaOH-treated gels (n=2-3) of samples from parasites co-incubated with 
inhibitors 1-4 and YnMyr. See Supp. Fig. S10 for example gels.  
Figure 7: Chemical proteomic analysis of YnMyr tagging in the presence of NMT inhibitors. 
BSF parasites were labelled with YnMyr in the presence of inhibitors 1 (5, 10, 100 nM) and 2 
(1, 5, 20 µM). Proteins were subject to CuAAC, base treatment, enrichment and on-bead 
digest in technical duplicate and analysed by LC-MS/MS with quantification by LFQ. a. 
Global data visualisation of data after filtering to retain only those proteins quantified in both 
YnMyr replicates and imputation of missing values (see Methods for details). Left: response 
to 100 nM inhibitor 1 plotted against enrichment over myristic acid (Myr) controls. Right: 
response to inhibitors 1 (100 nM) vs 2 (20 µM). Proteins containing an N-terminal glycine 
(MG) and those for which the YnMyr-modified peptide was identified using reagents AzRB or 
AzRTB are indicated. b. Dose-response plots (treatment with 1) for protein hits. Curves are 
colour-coded based on clustering (degree of response; see Supp. Fig. S12). c. Dose-
response plots (treatment with 1) for other MG proteins not assigned as hits (grey) and for 
outlier non-MG protein (Tb927.8.2250, black) that decreases only at high concentrations of 
inhibitors. See also Supp. Table S6 and Supp. Fig. S13 (dose-response curves for treatment 
with 2 and for ‘medium confidence’ hits). 
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